Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 43 (100.0%)

Trials by Status

recruiting133%
active_not_recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
completedphase_4

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

NCT02619760
active_not_recruitingphase_4

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

NCT03462498
recruitingphase_4

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

NCT05709626

Clinical Trials (3)

Showing 3 of 3 trials
NCT02619760Phase 4

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

Completed
NCT03462498Phase 4

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Active Not Recruiting
NCT05709626Phase 4

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3